Form 4: Vericel Corp: Chief Medical Officer Jonathan Hopper Reports Stock Transactions

Chief Medical Officer Jonathan Hopper reports transactions involving Vericel Corp stock, including the vesting of Restricted Stock Units (RSUs) and subsequent acquisition and disposal of shares to cover tax obligations.

Summary

• Jonathan Hopper, Chief Medical Officer of Vericel Corp, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• The reported transactions include the vesting of Restricted Stock Units (RSUs) granted on February 17, 2023, February 18, 2022 and February 19, 2021.
• As a result of RSU vesting, Hopper acquired shares of common stock.
• A portion of the vested shares were withheld by Vericel to satisfy tax withholding requirements.
• Hopper also deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
• Hopper's total beneficially owned shares after the reported transactions is 63,737.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions related to equity compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The vesting of RSUs indicates that Hopper is meeting the conditions of his equity compensation plan.
• The deferred compensation plan allows Hopper to defer income and potentially reduce his current tax liability.

Future Outlook

Remaining RSUs granted on February 17, 2023, will vest in annual installments on February 17, 2026, and February 17, 2027.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates standard compensation practices for Vericel's executives.

Comparison to Industry Standards

• Equity compensation, including RSUs, is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical industries, to align the interests of executives with those of shareholders.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize RSU grants as part of their executive compensation packages.
• The vesting schedules and tax withholding practices described in the filing are consistent with standard industry practices.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates